Viridian Therapeutics, Inc. stock is up 13.23% since 30 days ago. The next earnings date is Mar 6, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 57.14% of the previous 6 December’s closed higher than November. 100% of analysts rate it a buy.
Viridian Therapeutics, Inc. develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED) The company was founded in 2006 and is headquartered in Waltham, Massachusetts.